Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. Post author:Sam Post published:December 18, 2017 Post category:BioPharma The FDA broke new ground today with a first-of-its-kind therapy for eye disease. Source: BioSpace You Might Also Like FDA Grants New Clearance for NICO Corporation's Brain Surgery Technology January 31, 2017 Five Prime Tanked on Early Peek of Lead Drug Data November 7, 2017 Sanofi Falls Short of Q3 Expectations, Terminates Phase II Lung Drug From Pipeline November 1, 2017
